{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014242","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.692912+00:00","generated_at":"2026-06-24T05:02:29.484414+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kura Oncology Q2 net loss $34.8M; identifies ziftomenib Phase 2 dose, $450M cash runway through 2024","bullets":["Net loss of $34.8M in Q2 2022 vs. $33.7M in Q2 2021; R&D expenses rose to $24.3M.","Cash, cash equivalents and investments total $450.3M as of June 30, 2022, providing runway through 2024.","Recommended Phase 2 dose for ziftomenib identified, pending FDA review; additional 18 patients enrolled in KOMET-001 trial.","Preliminary activity observed in KURRENT-HN trial of tipifarnib + alpelisib; first patient dosed in HRAS overexpression cohort.","KURRENT-LUNG trial of tipifarnib + osimertinib to initiate in Q3; IND for KO-2806 expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014242","json":"https://secwatch.observer/filing/0000950170-22-014242.json","markdown":"https://secwatch.observer/filing/0000950170-22-014242.md","text":"https://secwatch.observer/filing/0000950170-22-014242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017022014242/0000950170-22-014242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017022014242/kura-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:02:29.484414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}